Part 3 - The Movement

Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed. In Part 3, Dr. Small sits down with patient advocate Lisa Salberg, founder of the Hypertrophic Cardiomyopathy Association (HCMA), to explore how a personal diagnosis evolved into a global movement—helping to establish more than 60 Centers of Excellence around the world.

The conversation reinforces why embedding the patient voice early is essential to advancing cardiovascular medicine.

Part 2 - The Shift

Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed. In Part 2, Dr. Small welcomes HCM expert Dr. Matthew Martinez and leading cardiologist Dr. Nani Bhalla. Together, they examine why HCM has historically been so difficult to detect—and what has changed in recent years to begin altering that trajectory.

The discussion explores how earlier recognition, paired with more precise and individualized treatment decisions, can change outcomes in meaningful and lasting ways.

Part 1 - The Moment

Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed. In Part 1, NFL tight end Tommy Sweeney shares his experience being diagnosed with HCM. He reflects on his personal journey— from diagnosis and treatment decision making to his return to the NFL with his condition appropriately treated and well managed. His story underscores a sobering reality: HCM can remain undetected even in individuals who receive frequent medical screenings, like elite athletes.

Highlights include: • Early detection and the potential of screening studies like PROMISE and iStopMM • Modifiable risk factors—how diet, exercise, and inflammation shape disease and outcomes • Emerging therapies on the horizon • Why “down with dex” and other old beliefs deserve retirement • The personal “why” behind every advance in myeloma care

About the Experts

Dr. Paul Richardson

Dr. Paul Richardson is an internationally recognized visionary in hematology and oncology whose trailblazing research at Dana-Farber Cancer Institute and Harvard Medical School has driven therapeutic revolutions in multiple myeloma, transforming patient outcomes and defining today’s standards of care. In addition to his involvement in the approval of nearly every major therapy for the disease over the past two decades, he is also one of the most prolific and cited experts in the field, with nearly 500 original articles and 400 reviews.

Dr. Richardson is a paid consultant for BMS.

Dr. Joseph Mikhael Dr. Joseph Mikhael has revolutionized and broadened access to world-class myeloma care globally through his pioneering leadership at TGen and the International Myeloma Foundation and as principal investigator of numerous groundbreaking clinical trials, setting new benchmarks in innovation, impact, and equity. Celebrated as a dynamic champion for underserved communities, an award-winning educator, and a masterful communicator, Dr. Mikhael has authored over 150 influential scientific articles and was recently recognized among America’s Top 100 Doctors for his transformational contributions to the field.

Dr. Mikhael was not compensated for his participation.

Dr. Mecide Gharibo

Dr. Mecide Gharibo is an innovative hematology leader whose passion for transforming patient care extends from academic clinical expertise at Rutgers Cancer Institute to launching breakthrough therapies as Global Head of Hematology at Bristol Myers Squibb. Renowned for advancing life-saving treatments and optimizing patient access, Dr. Gharibo’s clinical excellence and senior pharmaceutical leadership have fueled medical innovation and set new standards for care through a proven record of successful therapy approvals.

Dr. Gharibo is an employee of BMS.

Highlights include: • How MRD is reshaping drug development and accelerating innovation • The evolution of next-generation and targeted therapies with the goal of achieving deeper and more durable remissions • New thinking on “hit hard early” vs “save the best for last” treatment strategies • The impact of race, biology, and access on outcomes—and what’s changing that trajectory

If you want to understand the science, urgency, and humanity driving today’s breakthroughs, this episode is your front-row seat to the bleeding edge of discovery.

About the Experts

Dr. Paul Richardson

Dr. Paul Richardson is an internationally recognized visionary in hematology and oncology whose trailblazing research at Dana-Farber Cancer Institute and Harvard Medical School has driven therapeutic revolutions in multiple myeloma, transforming patient outcomes and defining today’s standards of care. In addition to his involvement in the approval of nearly every major therapy for the disease over the past two decades, he is also one of the most prolific and cited experts in the field, with nearly 500 original articles and 400 reviews.

Dr. Richardson is a paid consultant for BMS.

Dr. Joseph Mikhael Dr. Joseph Mikhael has revolutionized and broadened access to world-class myeloma care globally through his pioneering leadership at TGen and the International Myeloma Foundation and as principal investigator of numerous groundbreaking clinical trials, setting new benchmarks in innovation, impact, and equity. Celebrated as a dynamic champion for underserved communities, an award-winning educator, and a masterful communicator, Dr. Mikhael has authored over 150 influential scientific articles and was recently recognized among America’s Top 100 Doctors for his transformational contributions to the field.

Dr. Mikhael was not compensated for his participation.

Dr. Mecide Gharibo

Dr. Mecide Gharibo is an innovative hematology leader whose passion for transforming patient care extends from academic clinical expertise at Rutgers Cancer Institute to launching breakthrough therapies as Global Head of Hematology at Bristol Myers Squibb. Renowned for advancing life-saving treatments and optimizing patient access, Dr. Gharibo’s clinical excellence and senior pharmaceutical leadership have fueled medical innovation and set new standards for care through a proven record of successful therapy approvals.

Dr. Gharibo is an employee of BMS.

Dr. Tania Small sits down with Dr. Heinz-Josef Lenz, one of the world’s greatest minds in gastrointestinal medical research, for a thought-provoking conversation on the future of colorectal cancer (CRC) care.

Together, they unpack the rising incidence of early-onset CRC and the factors driving the surge of new cases in younger patients. This conversation dives into cutting-edge innovations that are reshaping detection and treatment:

• ctDNA liquid biopsies and minimal residual disease testing - revolutionizing how relapse is detected.
• Next-generation diagnostics and precision screening, including AI-assisted colonoscopies - enabling earlier, more accurate identification.
• Methylation profiling, tumor microenvironment and epigenetic therapies - advancing personalized therapy and novel treatments.
• Immunotherapies and targeted agents - moving to the “front line” with the potential to transform treatment approaches into organ-preserving strategies.

But the conversation doesn’t stop at science. Together, they examine the influence of lifestyle, disparities in access, and patient-driven data on survival.

If you're driving change in oncology, this episode offers practical insights on integrating molecular testing, rethinking prevention, and preparing for the innovations ahead.

About Dr Heinz-Josef Lenz

Heinz-Josef Lenz, MD, is an award-winning trailblazer and mentor whose pioneering work in colorectal cancer gene regulation, drug resistance, early detection and surveillance has reshaped the field of oncology. He is the recipient of multiple prestigious honors, including the ASCO Young Investigator Award, Career Development Award and the USC Mentoring Award, celebrating his excellence in both research and mentorship. Dr Lenz also serves on national committees including SWOG, NCI Task Forces and advisory boards and has authored numerous peer-reviewed publications.

Dr Lenz is a professor of medicine, Preventive Medicine and Cancer Biology J Terrence Lanni chair in Cancer Research. He is also deputy Cancer Center director at USC Norris and co-director of USC Brown Center for Cancer Drug Development.

Dr. Heinz-Josef Lenz is a paid BMS consultant.

In this special edition of DoctoRx Unscripted, Dr. Tania Small sits down with three of the most visionary leaders in oncology, Dr. Lillian Siu, Dr. Fabrice André and Dr. Howard “Skip” Burris for a provocative conversation on data that has the potential to redefine the future of cancer care. They unpack cutting-edge findings—from next-generation diagnostics and novel modalities to AI-powered trials, precision medicine, prevention and what’s coming next in oncology innovation. But the conversation goes beyond the data and tackles the decisions, behaviors and systems needed to shape real-world outcomes. They explore how lifestyle modifications may enhance treatment, efficacy and survival, and what it will take to improve global access to optimal cancer care and provide lasting impact through patient-driven science and purposeful action.

This unforgettable episode spotlights the potential breakthroughs poised to detect cancer earlier and challenge conventional paradigms, with the goal of delivering better outcomes for patients worldwide. If you're a clinician, researcher, or advocate at the forefront of oncology, this is your front-row seat to the future told by the pioneers shaping it. Dr. André, Dr. Burris and Dr. Siu are paid consultants for BMS.

Join Dr. Tania Small, in a compelling 2-part episode featuring Dr. George Grossberg, a world-renowned geriatric psychiatrist who's been at the forefront of Alzheimer’s disease research and innovation for over 40 years. With over 400 papers to his name, Dr. Grossberg brings unparalleled insights into the disease.

In part 2, they delve into groundbreaking science - from researching novel therapeutic targets and addressing Alzheimer’s psychosis to the power of patient-driven science in research and prevention.

It is a forward-looking conversation that equips you with new cutting-edge insights for the future.